Cancer vaccine enhanced, non-tumor-reactive CD8(+) T cells exhibit a distinct 
molecular program associated with "division arrest anergy"

Beyer, M.; Karbach, J.; Mallmann, M. R.; Zander, T.; Eggle, D.; Classen, S.; Debey-Pascher, S.; Famulok, M.; Jäger, E.; Schultze, J. L.

doi:10.1158/0008-5472.CAN-08-3796

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Cancer vaccine enhanced, non-tumor-reactive CD8(+) T cells exhibit a distinct molecular program associated with "division arrest anergy"

MPS-Authors

There are no MPG-Authors in the publication available

External Resource

http://www.ncbi.nlm.nih.gov/pubmed/19435912
(Any fulltext)

http://cancerres.aacrjournals.org/content/69/10/4346.full.pdf
(Any fulltext)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Beyer, M., Karbach, J., Mallmann, M. R., Zander, T., Eggle, D., Classen, S., et al. (2009). Cancer vaccine enhanced, non-tumor-reactive CD8(+) T cells exhibit a distinct molecular program associated with "division arrest anergy". Cancer research, 69(10), 4346-54. doi:10.1158/0008-5472.CAN-08-3796.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0028-6454-1

Abstract

Immune-mediated tumor rejection relies on fully functional T-cell responses and neutralization of an adverse tumor microenvironment. In clinical trials, we detected peptide-specific but non-tumor-reactive and therefore not fully functional CD8(+) T cells post-vaccination against tumor antigens. Understanding the molecular mechanisms behind nontumor reactivity will be a prerequisite to overcome this CD8(+) T-cell deviation. We report that these non-tumor-reactive CD8(+) T cells are characterized by a molecular program associated with hallmarks of "division arrest anergy." Non-tumor-reactive CD8(+) T cells are characterized by coexpression of CD7, CD25, and CD69 as well as elevated levels of lck(p505) and p27(kip1). In vivo quantification revealed high prevalence of non-tumor-reactive CD8(+) T cells with increased levels during cancer vaccination. Furthermore, their presence was associated with a trend toward shorter survival. Dynamics and frequencies of non-target-reactive CD8(+) T cells need to be further addressed in context of therapeutic vaccine development in cancer, chronic infections, and autoimmune diseases.